1. Home
  2. PD vs DBVT Comparison

PD vs DBVT Comparison

Compare PD & DBVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PagerDuty Inc.

PD

PagerDuty Inc.

HOLD

Current Price

$11.47

Market Cap

865.3M

Sector

Technology

ML Signal

HOLD

DBVT

DBV Technologies S.A.

N/A

Current Price

$14.27

Market Cap

948.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PD
DBVT
Founded
2009
2002
Country
United States
France
Employees
N/A
90
Industry
Computer Software: Prepackaged Software
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
865.3M
948.8M
IPO Year
2019
2014

Fundamental Metrics

Financial Performance
Metric
PD
DBVT
Price
$11.47
$14.27
Analyst Decision
Buy
Buy
Analyst Count
9
7
Target Price
$12.63
$32.04
AVG Volume (30 Days)
1.4M
387.1K
Earning Date
05-28-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
416.95
10.26
EPS
0.13
N/A
Revenue
$492,546,000.00
$5,636,000.00
Revenue This Year
$3.58
$35.04
Revenue Next Year
$2.88
$2,360.78
P/E Ratio
$91.31
N/A
Revenue Growth
5.36
35.77
52 Week Low
$5.70
$8.80
52 Week High
$17.29
$26.19

Technical Indicators

Market Signals
Indicator
PD
DBVT
Relative Strength Index (RSI) 60.80 46.98
Support Level $10.89 $12.75
Resistance Level $13.43 $14.68
Average True Range (ATR) 0.47 0.69
MACD 0.09 0.16
Stochastic Oscillator 80.18 74.63

Price Performance

Historical Comparison
PD
DBVT

About PD PagerDuty Inc.

PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the company derives a majority of its revenue from the United States and the rest from International markets.

About DBVT DBV Technologies S.A.

DBV Technologies SA is a clinical-stage specialty biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin. The therapeutic approach is based on epicutaneous immunotherapy or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin, an epicutaneous patch (i.e., a skin patch). Its main product candidate under development is Viaskin Peanut for the treatment of peanut-allergic patients. In addition, the company also has earlier-stage food allergy programs, including Viaskin Milk and Eosinophilic Esophagitis, or EoE.

Share on Social Networks: